Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946900 | 0.87 | AGTR1 (0.67) | AGTR1AGTR2 | |
| SCHEMBL9128117 | 0.83 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL8193124 | 0.83 | AGTR1 (0.49) | AGTR1AGTR2 | |
| SCHEMBL9128122 | 0.83 | AGTR1 (0.54) | AGTR1AGTR2 | |
| SCHEMBL951175 | 0.83 | AGTR1 (0.66) | AGTR1AGTR2 | |
| SCHEMBL8507705 | 0.81 | AGTR1 (0.56) | AGTR1AGTR2 | |
| SCHEMBL8260760 | 0.81 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL27406325 | 0.81 | AGTR1 (0.55) | AGTR1AGTR2 | |
| SCHEMBL9165250 | 0.80 | AGTR1 (0.72) | AGTR1AGTR2 | |
| SCHEMBL9120388 | 0.80 | AGTR1 (0.50) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137613-A1 | PROCESS FOR EPROSARTAN | HETERO DRUGS LIMITED (IN) | 2010-06-03 | — | — | US | disclosed |
| WO-2009122421-A2 | IMPROVED PROCESS FOR EPROSARTAN INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2009-10-08 | — | — | WO | disclosed |
| WO-2008078330-A1 | IMPROVED PROCESS FOR EPROSARTAN | HETERO DRUGS LIMITED (IN) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137613-A1 | PROCESS FOR EPROSARTAN | PTMA, PTGER1, PDGFRA | AGTR1 289/4885AGTR2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.